Teva Gets Mixed Reception as U.S. High Court Debates Copaxone
Oct. 15 (Bloomberg) — Teva Pharmaceutical Industries Ltd. got a mixed reception at a U.S. Supreme Court hearing as the company sought to preserve a patent that shields its top-selling Copaxone multiple-sclerosis drug from generic competition.
Hearing arguments today in Washington, the justices suggested they will divide on whether a federal appeals court was right to invalidate a patent that would protect Copaxone from rivals until September. Teva contends the appeals court should have deferred to the trial judge’s reading of the patent.
Several justices expressed support for Teva’s position while others voiced skepticism.
To contact the reporter on this story: Greg Stohr in Washington at gstohr@bloomberg.net
To contact the editor responsible for this story: Laurie Asseo at lasseo1@bloomberg.net
